The flow chart of study selection process. by Junyin Pan (20700411)

Subjects:

Data extracted from included studies for the systematic review and meta-analysis. by Junyin Pan (20700411)

Subjects:

Specifications and outcomes of clinical trial studies included in the meta-analysis. by Junyin Pan (20700411)

Subjects:

Procedure to capture digital images of the body color of ornamental shrimp. by Wei-Wei Hou (3405947)

Subjects:

Composition of experimental diets fed to cherry shrimp (<i>N</i>. <i>davidi</i> var. red) including varying concentrations of astaxanthin and <i>Bidens pilosa</i> extract over a 8-... by Wei-Wei Hou (3405947)

Subjects:

Analysis of color parameters (<i>L</i>, <i>a</i>, <i>b</i>*) and color difference (Δ<i>E</i>*_<i>ab</i>) values^a before and after hypoxic stress in cherry shri... by Wei-Wei Hou (3405947)

Subjects:

Changes in the body color of cherry shrimp (<i>N</i>. <i>davidi</i> var. red) across different feed treatment groups (Control, AX100, AX100 + BP, AX200, AX200 + BP) over time. by Wei-Wei Hou (3405947)

Subjects:

Analysis of stress-related gene expression in cherry shrimp (<i>N</i>. <i>davidi</i> var. red). by Wei-Wei Hou (3405947)

Subjects:

Expression analysis of color-related genes in the hepatopancreas and shell tissues of cherry shrimp (<i>N</i>. <i>davidi</i> var. red) fed with vehicle, astaxanthin alone and in co... by Wei-Wei Hou (3405947)

Subjects:

Correlations between feed additives and color-related genes. by Wei-Wei Hou (3405947)

Subjects:

Two-dimensional quadrant analysis of cherry shrimp (<i>N</i>. <i>davidi</i> var. red) bodycolor parameters (<i>L*</i> and <i>a*</i> values) in different feed treatment groups on da... by Wei-Wei Hou (3405947)

Subjects:

Appearance and body color of <i>N</i>. <i>davidi</i> var. red. by Wei-Wei Hou (3405947)

Subjects:

Color data collection points on the body of ornamental shrimp. by Wei-Wei Hou (3405947)

Subjects:

Changes in the color parameters of cherry shrimp (<i>N</i>. <i>davidi</i> var. red) in different feed treatment groups^a over a 56-day period (mean ± SD, <i>n</i> = 20). by Wei-Wei Hou (3405947)

Subjects:

Trends over 10 years (2011–2021) in clinical characteristics of children with severe acute malnutrition admitted at Moyo NRU. by Mphatso Nancy Chisala (20477275)

Trends over 10 years in children with severe acute malnutrition admitted at Moyo NRU. by Mphatso Nancy Chisala (20477275)

Blood Pressure and LDL-C During Follow-up. by Karl Ingard (22582091)

“…During a mean follow-up of 3.8 years, 31.7% (n = 64) of the patients in the intervention group and 37.5% (n = 72) in the control group reached the primary endpoint (HR 0.82, 95% CI 0.58–1.14, <i>P</i> = 0.23). The risk of cardiovascular death was significantly decreased (HR 0.64, 95% CI 0.41–0.998, <i>P</i> = 0.049) and the risk of fracture non-significantly increased (HR 1.47, 95% CI 0.95–2.27, <i>P</i> = 0.08) in the intervention group compared to the control group.…”

Baseline Characteristics of Included Patients. by Karl Ingard (22582091)

“…During a mean follow-up of 3.8 years, 31.7% (n = 64) of the patients in the intervention group and 37.5% (n = 72) in the control group reached the primary endpoint (HR 0.82, 95% CI 0.58–1.14, <i>P</i> = 0.23). The risk of cardiovascular death was significantly decreased (HR 0.64, 95% CI 0.41–0.998, <i>P</i> = 0.049) and the risk of fracture non-significantly increased (HR 1.47, 95% CI 0.95–2.27, <i>P</i> = 0.08) in the intervention group compared to the control group.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”